Cadila Pharmaceuticals
Biosimilar developer, India. 2 development products across 2 molecules: filgrastim, insulin human.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Filgrastim | Cadila Pharmaceuticals filgrastim | · | · | · | · | · | Oct 2013 | · | 1/7 |
| Insulin human | Cadila Pharmaceuticals human insulin | · | · | · | · | · | Nov 2024 | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Companies on the same molecules
Developers whose portfolios overlap most with Cadila Pharmaceuticals, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- CDSCOOct 2013Cadila Pharmaceuticals (INN only), filgrastim
- CDSCONov 2024Cadila Pharmaceuticals (INN only), insulin human
Compare Cadila Pharmaceuticals with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant